TP53 and cancer: Since TP53 is the most frequently altered gene in human tumours27, with mutations arising both early in tumorigenesis, such as in glioblastoma and ovarian cancers28–30, as well as late during cancer progression28,31, it is critical to understand the impact of TP53 mutations on cellular competition.